Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430027 · ClinicalTrials.gov registry record · NA
Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma
A NA study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT00430027 is a NA study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 8 participants.
The verdict
NCT00430027, a NA study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective of this pilot study is to determine whether neoadjuvant capecitabine/oxaliplatin/cetuximab and external beam radiation therapy followed by surgical resection \[and then followed by post operative adjuvant capecitabine, oxaliplatin and cetuximab\] is feasible and tolerable.
Interventions
- DRUG Capecitabine
- DRUG Oxaliplatin
- DRUG Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00430027
The ClinicalTrials.gov registry entry for NCT00430027 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Capecitabine is the first listed.
NCT00430027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00430027 about?
NCT00430027 is a clinical study titled "Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma". The primary objective of this pilot study is to determine whether neoadjuvant capecitabine/oxaliplatin/cetuximab and external beam radiation therapy followed by surgical resection \[and then followed by post operative adjuvant capecitabine, oxaliplatin and cetuximab\] is feasible and tolerable.
What is the current status of trial NCT00430027?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2006-11. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00430027?
The interventions under investigation include: Capecitabine (DRUG), Oxaliplatin (DRUG), Cetuximab (DRUG).
Who is sponsoring clinical trial NCT00430027?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.